“Q4 of 2023 and 2024 will be pivotal for Cybin as we expect topline clinical data readouts from both our Phase 1/2a trial of CYB003 — our deuterated psilocybin analog — and from our Phase 1 trial of CYB004 and SPL028: our deuterated DMT programs," said Cybin CEO Doug Drysdale "Cybin now has access to over US$100 million, capital expected to provide the cash runway needed to complete these value-driving clinical milestones and to continue focusing on clinical execution with the ultimate goal of bringing improved therapeutic options to patients in need." Learn more: https://lnkd.in/dpdi8BJt #ChangingMinds #researchanddevelopment #cybin #psychedelicresearch #clinicalresearch #mentalhealthresearch #CybinInc #DrugDevelopment #Biotech #MentalHealth
It will be exciting to see the data!
CEO @ Semgeeks | Helping b2b & b2c companies Implement a Demand Generation Strategy to Maximize ROI & Growth
11moGood work, Cybin team. This is a capital game as much as it is a science game. Keep focused